IP Library Granted Patent US 9,051,566
Granted Patent B2
US 9,051,566 · App. 10/762,395 · Granted Jun 9, 2015

Post-transcriptional gene silencing using expressed double stranded RNA

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,566
App. No.
10/762,395
Granted
Jun 9, 2015
Kind
B2
Abstract

Described herein are methods for identifying nucleic acid sequences that modulate the function of a cell, the expression of a gene in a cell, or the biological activity of a target polypeptide in a cell. The methods involve the use of double stranded RNA expression libraries, double stranded RNA molecules, and post-transcriptional gene silencing techniques.

Claims (9)

1. A method comprising:

introducing into a population of RNA stress response-competent cells an expression vector comprising a promoter sequence operably linked to a coding sequence for a nucleic acid less than 50 nucleotides in length for expression of a double stranded hairpin RNA, wherein one strand of the double stranded portion of the hairpin RNA is complementary to a target gene mRNA in the cell, and wherein the hairpin RNA downregulates expression of the target RNA when expressed from the introduced expression vector, wherein the level of apoptosis in the population of cells in which the hairpin RNA is expressed is lower than the level of apoptosis in a population of cells transfected with the same double stranded hairpin RNA produced outside the cell.

2. The method of claim 1 , wherein said target gene is a pathogen gene.

3. The method of claim 1 , wherein said RNA stress response-competent cell is a vertebrate cell.

4. The method of claim 3 , wherein said vertebrate RNA stress response-competent cell is a mammalian cell.

5. The method of claim 1 , wherein said double stranded hairpin RNA is expressed as a single transcript that contains an inverted repeat.

6. The method of claim 1 , wherein expression of said target gene is decreased at least 50%.

7. The method of claim 6 , wherein expression of said target gene is decreased 90%.

8. The method of claim 1 , wherein the population of RNA stress response-competent cells is ex vivo.

Assignments (4)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2009
From: NUCLEONICS, INC.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 022386/0468 →
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2008
From: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; S.R. ONE, LIMITED; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
To: NUCLEONICS, INC.
Reel/Frame 021932/0001 →
SECURITY AGREEMENT Recorded Sep 29, 2008
From: NUCLEONICS, INC.
To: NEW ENTERPRISE ASSOCIATES 10, LIMITED PARTNERSHIP; S.R. ONE, LIMITED; OFCO CLUB IV; HEALTHCAP IV KB; HEALTHCAP IV, L.P.; HEALTHCAP IV BIS, L.P.; BURRILL LIFE SCIENCES CAPITAL FUND, L.P.; BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.; QUAKER BIOVENTURES, L.P.; QUAKER BIOVENTURES TOBACCO FUND, L.P.; POSCO BIOVENTURES I, L.P.
Reel/Frame 021602/0423 →